NRx Pharmaceuticals CCO Robert Besthof resigns; hires Windhaul Partners for commercial strategy

NRX Pharmaceuticals, Inc.

Robert Besthof, Head of Operations and CCO, resigned effective Feb 16, 2023; will stay for transition.
Company in discussions with Besthof for part-time advisor role.
Hired Windhaul Partners and President Frank Sanders (ex-Sage Therapeutics) to advise on expanded commercial plan.
FDA recommended expanded 'Chronic/Intermittent' indication for lead compound NRX-101, prompting expanded commercial strategy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Besthof

Head of Operations and Chief Commercial Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2023-02-16
Filed: February 23, 2023, 6:59 PM ET

On February 16, 2023, Mr. Robert Besthof, NRx Pharmaceuticals, Inc.’s (the “Company”) Head of Operations and Chief Commercial Officer, notified the Company of his resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Besthof resigned as Head of Operations and Chief Commercial Officer at NRX Pharmaceuticals, Inc..

Action: resigned
Role: Head of Operations and Chief Commercial Officer

Exact text from the filing

On February 16, 2023, Mr. Robert Besthof, NRx Pharmaceuticals, Inc.’s (the “Company”) Head of Operations and Chief Commercial Officer, notified the Company of his resignation.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950142-23-000510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.